LAS VEGAS--(BUSINESS WIRE)--May 4, 2006--CardioVascular BioTherapeutics Inc. (OTCBB: CVBT - News) announced it will be presenting its latest medical updates on drug candidates formulated with Cardio Vascu-Grow(TM), a potent protein growth factor that stimulates the growth of new blood vessels. These drug candidates are possible new treatments for diseases that could benefit patients by providing increased perfusion of blood for such conditions as cardiovascular disease, lumbar ischemia, stroke, peripheral vascular disease and impaired wound healing. Dan Montano, president of CVBT, stated, "We believe CVBT has a major medical breakthrough to treat heart attacks, stroke, kidney failure and more, by growing new blood vessels around a tissue or organ. We are making progress every month toward our goal of U.S. FDA approval for our treatments in heart, legs, wound healing, stroke and back pain. We look forward to informing the Money Show attendees of our progress."
